351 related articles for article (PubMed ID: 17142350)
1. Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.
McMurtry MS; Moudgil R; Hashimoto K; Bonnet S; Michelakis ED; Archer SL
Am J Physiol Lung Cell Mol Physiol; 2007 Apr; 292(4):L872-8. PubMed ID: 17142350
[TBL] [Abstract][Full Text] [Related]
2. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
Cheng G; Wang X; Li Y; He L
Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
[TBL] [Abstract][Full Text] [Related]
3. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
[TBL] [Abstract][Full Text] [Related]
4. Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension.
Bisserier M; Katz MG; Bueno-Beti C; Brojakowska A; Zhang S; Gubara S; Kohlbrenner E; Fazal S; Fargnoli A; Dorfmuller P; Humbert M; Hata A; Goukassian DA; Sassi Y; Hadri L
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502015
[TBL] [Abstract][Full Text] [Related]
5. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR
Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated zinc and sphingosine-1-phosphate signaling in pulmonary hypertension: Potential effects by targeting of bone morphogenetic protein receptor type 2 in pulmonary microvessels.
Tran HB; Maiolo S; Harper R; Zalewski PD; Reynolds PN; Hodge S
Cell Biol Int; 2021 Nov; 45(11):2368-2379. PubMed ID: 34347342
[TBL] [Abstract][Full Text] [Related]
7. Reversal of MicroRNA Dysregulation in an Animal Model of Pulmonary Hypertension.
Gubrij IB; Pangle AK; Pang L; Johnson LG
PLoS One; 2016; 11(1):e0147827. PubMed ID: 26815432
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-mediated Bmpr2 point mutation exacerbates late pulmonary vasculopathy and reduces survival in rats with experimental pulmonary hypertension.
Kabwe JC; Sawada H; Mitani Y; Oshita H; Tsuboya N; Zhang E; Maruyama J; Miyasaka Y; Ko H; Oya K; Ito H; Yodoya N; Otsuki S; Ohashi H; Okamoto R; Dohi K; Nishimura Y; Mashimo T; Hirayama M; Maruyama K
Respir Res; 2022 Apr; 23(1):87. PubMed ID: 35395852
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension.
Bisserier M; Mathiyalagan P; Zhang S; Elmastour F; Dorfmüller P; Humbert M; David G; Tarzami S; Weber T; Perros F; Sassi Y; Sahoo S; Hadri L
Circulation; 2021 Jul; 144(1):52-73. PubMed ID: 34078089
[TBL] [Abstract][Full Text] [Related]
10. Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension.
Morty RE; Nejman B; Kwapiszewska G; Hecker M; Zakrzewicz A; Kouri FM; Peters DM; Dumitrascu R; Seeger W; Knaus P; Schermuly RT; Eickelberg O
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1072-8. PubMed ID: 17347486
[TBL] [Abstract][Full Text] [Related]
11. Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
Hautefort A; Mendes-Ferreira P; Sabourin J; Manaud G; Bertero T; Rucker-Martin C; Riou M; Adão R; Manoury B; Lambert M; Boet A; Lecerf F; Domergue V; Brás-Silva C; Gomez AM; Montani D; Girerd B; Humbert M; Antigny F; Perros F
Circulation; 2019 Feb; 139(7):932-948. PubMed ID: 30586714
[TBL] [Abstract][Full Text] [Related]
12. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension.
Reynolds AM; Holmes MD; Danilov SM; Reynolds PN
Eur Respir J; 2012 Feb; 39(2):329-43. PubMed ID: 21737550
[TBL] [Abstract][Full Text] [Related]
13. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Wang Y; Zhang XH; Wang HL
Can J Physiol Pharmacol; 2011 May; 89(5):345-54. PubMed ID: 21619414
[TBL] [Abstract][Full Text] [Related]
14. BMPR2 gene therapy for PAH acts via Smad and non-Smad signalling.
Harper RL; Reynolds AM; Bonder CS; Reynolds PN
Respirology; 2016 May; 21(4):727-33. PubMed ID: 26809239
[TBL] [Abstract][Full Text] [Related]
15. The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient.
Happé C; Kurakula K; Sun XQ; da Silva Goncalves Bos D; Rol N; Guignabert C; Tu L; Schalij I; Wiesmeijer KC; Tura-Ceide O; Vonk Noordegraaf A; de Man FS; Bogaard HJ; Goumans MJ
Cells; 2020 Jun; 9(6):. PubMed ID: 32521690
[No Abstract] [Full Text] [Related]
16. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
Long L; Crosby A; Yang X; Southwood M; Upton PD; Kim DK; Morrell NW
Circulation; 2009 Feb; 119(4):566-76. PubMed ID: 19153267
[TBL] [Abstract][Full Text] [Related]
17. Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension.
Maruyama H; Dewachter C; Belhaj A; Rondelet B; Sakai S; Remmelink M; Vachiery JL; Naeije R; Dewachter L
J Heart Lung Transplant; 2015 Mar; 34(3):468-78. PubMed ID: 25447587
[TBL] [Abstract][Full Text] [Related]
18. Impaired Interleukin-15 Signaling via
Hilton LR; Rätsep MT; VandenBroek MM; Jafri S; Laverty KJ; Mitchell M; Theilmann AL; Smart JA; Hawke LG; Moore SD; Renaud SJ; Soares MJ; Morrell NW; Ormiston ML
Hypertension; 2022 Nov; 79(11):2493-2504. PubMed ID: 36043416
[TBL] [Abstract][Full Text] [Related]
19. Dysregulated Smooth Muscle Cell BMPR2-ARRB2 Axis Causes Pulmonary Hypertension.
Wang L; Moonen JR; Cao A; Isobe S; Li CG; Tojais NF; Taylor S; Marciano DP; Chen PI; Gu M; Li D; Harper RL; El-Bizri N; Kim YM; Stankunas K; Rabinovitch M
Circ Res; 2023 Mar; 132(5):545-564. PubMed ID: 36744494
[TBL] [Abstract][Full Text] [Related]
20. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis.
McMurtry MS; Bonnet S; Wu X; Dyck JR; Haromy A; Hashimoto K; Michelakis ED
Circ Res; 2004 Oct; 95(8):830-40. PubMed ID: 15375007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
